1: Am J Hypertens. 1991 Jun;4(6):508-15. 

Renal effects of ANF (95-126), a new atrial peptide analogue, in dogs with
experimental heart failure.

Villarreal D, Freeman RH, Johnson RA.

Department of Physiology, University of Missouri School of Medicine, Columbia
65212.

Atrial natriuretic factor 95-126 [ANF (95-126)] is a novel 32 amino acid peptide
which is thought to originate from the kidney. The systemic hemodynamic and
renal effects of equimolar doses of intravenous synthetic ANF (95-126) and
synthetic alpha ANF (99-126) were examined in normal dogs (n = 6) and in dogs
with an arteriovenous (AV) fistula and chronic compensated high-output heart
failure (n = 5). ANF (95-126) and alpha ANF (99-126) were infused at 5 and 10
pmol/kg/min for 75-min periods each. In the normal and AV fistula dogs the two
peptides similarly decreased mean arterial pressures and right atrial pressures
(P less than .05). Creatinine clearance and urinary volume excretion increased
(P less than .05) in the normal dogs with both peptides, but only ANF (95-126)
produced significant elevations (P less than .05) of these two parameters in the
AV fistula animals. With the highest infusion dose, ANF (95-126) increased
urinary sodium excretion to at least twice the levels observed with alpha ANF
(99-126) in both groups of dogs (P less than .05). The decreases in plasma renin
and aldosterone were comparable for the two peptides in both groups of animals.
These results indicate that ANF (95-126) is more potent than alpha ANF (99-126)
for the promotion of a natriuresis, particularly in AV fistula dogs with
compensated high-output heart failure, in which the sodium excretory actions of
alpha ANF (99-126) were attenuated markedly.

PMID: 1831368 [PubMed - indexed for MEDLINE]